Currently, SGLT2 inhibitors have become a new mainstay in the treatment of T2DM (7), especially in combination with cardiovascular and renal disease, where SGLT2 inhibitors offer important benefits (8, 9). Here, SLC5A2 is linked to kidney disorder.